The goal of this prospective observational study is to evaluate whether injections of stem cells derived from the patient's own fat tissue (adipose tissue) can improve erectile function in men aged 30 to 75 who have erectile dysfunction (ED) and have not responded well to standard treatments like PDE-5 inhibitors (e.g., Viagra).
The main questions the study aims to answer are:
Will the stem cell injections improve erectile function, as measured by the International Index of Erectile Function (IIEF) score? Are there any changes in blood flow to the penis, which will be measured using a Doppler ultrasound?
Participants will:
Receive injections of their own stem cells (obtained from a biopsy of fat) directly into the penis.
Undergo assessments to check erectile function before and after treatment. Have follow-up visits at 3, 6, 9, and 12 months to monitor long-term effects. The study will also look for any possible side effects or complications and evaluate biological markers in the penis that may indicate the effectiveness of the treatment.
Participants will be recruited from clinic where they are already receiving care for ED. To take part, they must be in good overall health, with no severe heart disease, uncontrolled diabetes, cancer, or other conditions that could make stem cell therapy unsafe for them.
Age: Adult males aged 30 to 75 years.
Diagnosis: Confirmed diagnosis of erectile dysfunction (ED) of mild to moderate severity, as defined by an International Index of Erectile Function (IIEF) score.
Treatment Response: Failure or suboptimal response to conventional ED treatments, such as PDE-5 inhibitors.
General Health: Overall good health without contraindications to stem cell therapy.
Severe Cardiovascular Disease: Presence of severe cardiovascular conditions, including uncontrolled hypertension or significant heart disease.
Active Infections: Ongoing infections that could interfere with treatment or pose a risk to the participant.
Malignancies: History of or current cancer, including malignancies that could affect safety or treatment outcomes.
Contraindications to Stem Cell Therapy: Any medical conditions or treatments that contraindicate the use of stem cell therapy.
The study population will consist of men aged 30 to 75 years with a clinical diagnosis of mild to moderate erectile dysfunction (ED). Eligible participants are those who have experienced suboptimal or no response to standard therapies, including phosphodiesterase type 5 (PDE-5) inhibitors. The inclusion criteria are designed to focus on individuals most likely to benefit from regenerative therapy while ensuring safety. Participants will be recruited from Dr. Ranjith Ramasamy's clinic, where they are actively seeking care for erectile dysfunction. This population is expected to represent a diverse group of patients with varying etiologies of ED, including vascular, neurogenic, and idiopathic causes.
Cohort
Prospective
Autologous Adipose Tissue-Derived Stem Cell Injection for Erectile Dysfunction
Procedure/SurgeryThis intervention involves the use of autologous adipose tissue-derived stem cells (ADSC) to treat erectile dysfunction. The process begins with a minimally invasive liposuction procedure to harvest fat tissue from the participant\'s own body. The harvested fat is then processed to isolate stem cells, which are subsequently injected directly into the erectile tissue of the penis. This approach aims to enhance erectile function by promoting tissue regeneration and improving blood flow. Unlike other treatments for erectile dysfunction, this intervention uses stem cells derived from the participant\'s own fat, which may reduce the risk of immune rejection and offer a novel regenerative therapy option. The treatment is designed to address ED in patients who have not responded adequately to conventional therapies like PDE-5 inhibitors.
Stem cell-derived Exosomes Injection for Erectile Dysfunction
Procedure/SurgeryThis intervention involves the use of stem cell-derived exosomes to treat erectile dysfunction. Exosomes are nano-sized extracellular vesicles secreted by stem cells, containing bioactive molecules such as growth factors and signaling proteins that promote tissue repair and regeneration. Unlike therapies requiring the transplantation of live cells, this cell-free approach eliminates the need for invasive harvesting procedures. The exosomes are carefully purified from cultured stem cells and prepared for direct injection into the erectile tissue of the penis. This approach aims to enhance erectile function by stimulating tissue regeneration, reducing inflammation, and improving blood flow. Unlike other treatments for erectile dysfunction, exosome therapy offers a novel regenerative option, potentially benefiting patients who have not responded adequately to conventional therapies such as PDE-5 inhibitors.
Change in Erectile Function as Measured by the International Index of Erectile Function (IIEF) Score
The primary outcome measure for this study is the change in erectile function as assessed by the International Index of Erectile Function (IIEF) score. The IIEF is a validated questionnaire designed to evaluate various aspects of sexual health, including erectile function, sexual satisfaction, and overall sexual performance. Participants will complete the IIEF questionnaire at baseline and at follow-up visits to track changes in erectile function over time. The goal is to determine whether the intracavernosal injection of autologous adipose tissue-derived stem cells leads to significant improvements in erectile function compared to pre-treatment levels. The IIEF score will provide a comprehensive measure of treatment effectiveness and help assess the impact of the intervention on participants\' sexual health and quality of life.
Penile Hemodynamics as Measured by Doppler Ultrasound
The secondary outcome measure for this study is penile hemodynamics assessed by Doppler ultrasound. Doppler ultrasound is a non-invasive imaging technique used to evaluate blood flow and vascular function in the penis. This assessment will be conducted at baseline and during follow-up visits to determine changes in penile blood flow and vascular characteristics following the intracavernosal injection of autologous adipose tissue-derived stem cells. Improvements in penile hemodynamics, such as increased blood flow and better vascular function, will be used to gauge the effectiveness of the stem cell therapy in enhancing erectile function. This measure will complement changes in the International Index of Erectile Function (IIEF) score and provide a detailed understanding of the physiological effects of the treatment.
Click on the lead sponsor to view all of their trials.
